Diagnosis of Gastric Cancer by Serum Proteomic Fingerprinting

Gastroenterology

Volumn 130, Issue 6, 2006, Pages 1858-1864

  Poon, Terence C W ^a,b   Sung, Joseph J Y ^a,b   Chow, Shuk M ^a,b   Ng, Enders K W ^a,b   Yu, Alex C W ^a,b   Chu, Eagle S H ^a,b   Hui, Angela M Y ^a,b   Leung, Wai K ^a,b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER DIAGNOSIS; CATION EXCHANGE; CONTROLLED STUDY; HUMAN; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY ANALYSIS; STATISTICAL SIGNIFICANCE; STOMACH CANCER; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

EID: 33646366203     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2006.02.011     Document Type: Article

References (21)

1. Genta R.M. Screening for gastric cancer. does it make sense?. Aliment Pharmacol Ther 20 (2004) 42-47
2. Marrelli D., Roviello F., De Stefano A., Farnetani M., Garosi L., Messano A., and Pinto E. Prognostic significance of CEA, CA 19-9 and CA72-4 preoperative serum levels in gastric carcinoma. Oncology 57 (1999) 55-62
3. Marrelli D., Pinto E., De Stefano A., Farnetani M., Garosi L., and Roviello F. Clinical utility of CEA, CA 19-9, and CA 72-4 in the follow-up of patients with resectable gastric cancer. Am J Surg 181 (2001) 16-19
4. Ishigami S., Natsugoe S., Hokita S., Che X., Tokuda K., Nakajo A., Iwashige H., Tokushige M., Watanabe T., Takao S., and Aikou T. Clinical importance of preoperative carcinoembryonic antigen and carbohydrate antigen 19-9 levels in gastric cancer. J Clin Gastroenterol 32 (2001) 41-44
5. Gaspar M.J., Arribas I., Coca M.C., and Diez-Alonso M. Prognostic value of carcinoembryonic antigen, CA 19-9 and CA 72-4 in gastric carcinoma. Tumour Biol 22 (2001) 318-322
6. Petricoin III E.F., Ardekani A.M., Hitt A.B., Levine P.J., Fusaro V.A., Steinberg S.M., Mills G.B., Simone C., Fishman D.A., Kohn E.C., and Liotta L.A. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359 (2002) 572-577
7. Poon T.C.W., Yip T.T., Chan A.T.C., Yip C., Yip V., Mok T.S.K., Lee C.C.Y., Leung T.W.T., Ho S.K.W., and Johnson P.J. Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes. Clin Chem 49 (2003) 752-760
8. Poon T.C.W., Chan K.C.A., Ng P.C., Chiu R.W., Ang I.L., Tong Y.K., Ng E.K.O., Cheng F.W.T., Li A.M., Hon E.K.L., Fok T.F., and Lo Y.M.D. Serial analysis of plasma proteomic signatures in pediatric patients with severe acute respiratory syndrome and correlation with viral load. Clin Chem 50 (2004) 1452-1455
9. Sobin L.H., and Wittekind C.H. TNM classification of malignant tumors. 5th ed (1997), John Wiley & Sons, New York 170-173
10. Poon T.C.W., Hui A.Y., Chan H.L.Y., Ang I.L., Chow S.M., Wong N., and Sung J.J.Y. Prediction of liver fibrosis and cirrhosis in chronic hepatitis B infection by serum proteomic fingerprinting. a pilot study. Clin Chem 51 (2005) 328-335
11. Tusher V.G., Tibshirani R., and Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 98 (2001) 5116-5121
12. Varis K., Sipponen P., Laxen F., Samloff I.M., Huttunen J.K., Taylor P.R., Heinonen O.P., Albanes D., Sande N., Virtamo J., Harkonen M., and Helsinki Gastritis Study Group. Implications of serum pepsinogen I in early endoscopic diagnosis of gastric cancer and dysplasia. Scand J Gastroenterol 9 (2000) 950-956
13. Bodger K., Wyatt J.I., and Heatley R.V. Variation in serum pepsinogens with severity and topography of Helicobacter pylori-associated chronic gastritis in dyspeptic patients referred for endoscopy. Helicobacter 6 (2001) 216-224
14. Miki K., Morita M., Sasajima M., Hoshina R., Kanda E., and Urita Y. Usefulness of gastric cancer screening using the serum pepsinogen test method. Am J Gastroenterol 98 (2003) 735-739
15. Lee T.L., Leung W.K., Chan M.W.Y., Ng E.K.W., Tong J.H.M., Lo K.W., Chung S.C.S., Sung J.J.Y., and To K.F. Detection of gene promoter hypermethylation in the tumor and serum of patients with gastric carcinoma. Clin Cancer Res 8 (2002) 1761-1766
16. Ebert M.P., Meuer J., Wiemer J.C., Schulz H.U., Reymond M.A., Traugott U., Malfertheiner P., and Rocken C. Identification of gastric cancer patients by serum protein profiling. J Proteome Res 3 (2004) 1261-1266
17. Diamandis E.P. Analysis of serum proteomic patterns for early cancer diagnosis. drawing attention to potential problems. J Natl Cancer Inst 96 (2004) 353-356
18. Tolson J., Bogumil R., Brunst E., Beck H., Elsner R., Humeny A., Kratzin H., Deeg M., Kuczyk M., Mueller G.A., Mueller C.A., and Flad T. Serum protein profiling by SELDI mass spectrometry. detection of multiple variants of serum amyloid alpha in renal cancer patients. Lab Invest 84 (2004) 845-856
19. Cho W.C., Yip T.T., Yip C., Yip V., Thulasiraman V., Ngan R.K., Yip T.T., Lau W.H., Au J.S., Law S.C., Cheng W.W., Ma V.W., and Lim C.K. Identification of serum amyloid a protein as a potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteomic profiling. Clin Cancer Res 10 (2004) 43-52
20. Le L., Chi K., Tyldesley S., Flibotte S., Diamond D.L., Kuzyk M.A., and Sadar M.D. Identification of serum amyloid A as a biomarker to distinguish prostate cancer patients with bone lesions. Clin Chem 51 (2005) 695-707
21. Lannergard A., Larsson A., Kragsbjerg P., and Friman G. Correlations between serum amyloid A protein and C-reactive protein in infectious diseases. Scand J Clin Lab Invest 63 (2003) 267-272